Last updated: August 12, 2026
The fixed-dose combination of isosorbide dinitrate and hydralazine hydrochloride is an established oral heart-failure product marketed in the United States as BiDil and through generic equivalents. Its commercial opportunity is concentrated in low-cost immediate-release tablets, adherence-oriented packaging, differentiated excipient systems, and non-U.S. regulatory filings rather than core active-ingredient exclusivity.
The formulation must address several technical constraints: high tablet burden, frequent dosing, moisture sensitivity, nitrite-related degradation risk, taste and handling concerns, and the need to maintain rapid release of both active ingredients. The strongest commercial positioning is likely to come from manufacturing efficiency, stable high-volume supply, patient-friendly packaging, and regional regulatory execution.
What is the isosorbide dinitrate and hydralazine hydrochloride product?
The product combines two vasodilators:
| Component |
Pharmacologic role |
Typical BiDil strength |
| Isosorbide dinitrate |
Nitrate vasodilator that increases nitric oxide-mediated vascular relaxation |
20 mg |
| Hydralazine hydrochloride |
Direct arterial vasodilator |
37.5 mg |
| Product type |
Immediate-release oral tablet |
Fixed-dose combination |
BiDil is indicated with other heart-failure therapies for improving survival, reducing hospitalization for heart failure, and improving quality of life in self-identified Black patients with New York Heart Association Class III or IV heart failure receiving standard therapy. The approved regimen is one tablet three times daily, with titration to two tablets three times daily if tolerated.[1]
The dosing schedule creates a commercial opening for packaging, adherence tools, and formulation development. It also limits the product’s convenience relative to once-daily heart-failure therapies.
What excipients are used in BiDil tablets?
The BiDil prescribing information identifies conventional direct-compression excipients, including microcrystalline cellulose, crospovidone, magnesium stearate, and colloidal silicon dioxide.[1] The exact inactive-ingredient profile must be confirmed against the current FDA labeling and DailyMed listing for the marketed product because formulation and supplier details can change.
Core excipient functions
| Excipient |
Primary function |
Commercial rationale |
| Microcrystalline cellulose |
Diluent and dry binder |
Supports direct compression and tablet mechanical strength |
| Crospovidone |
Superdisintegrant |
Promotes rapid tablet breakup and immediate release |
| Colloidal silicon dioxide |
Glidant and moisture-management aid |
Improves powder flow and may reduce manufacturing variability |
| Magnesium stearate |
Lubricant |
Reduces sticking and ejection force during compression |
| Colorant, where used |
Product identification |
Supports differentiation between strengths and helps medication recognition |
The baseline formulation is strategically attractive because it uses widely available, compendial excipients and a conventional tablet process. That reduces regulatory and supply-chain complexity compared with a novel delivery system.
What excipient strategy is best for this combination?
The preferred strategy is a robust immediate-release direct-compression platform with low excipient complexity. The objective is to preserve rapid dissolution while controlling blend uniformity, tablet friability, capping, moisture uptake, and lubricant sensitivity.
Diluent and binder selection
Microcrystalline cellulose is suitable for the relatively high total drug load. The combination contains 57.5 mg of active ingredients per tablet at the marketed strength, leaving sufficient formulation space for a standard tablet.
Potential alternatives include:
- Anhydrous dibasic calcium phosphate for improved flow and reduced moisture sensitivity.
- Spray-dried lactose for enhanced compactability.
- Mannitol for a cleaner mouthfeel if an orally disintegrating or chewable concept is pursued.
- Coprocessed cellulose-silicon dioxide systems for improved flow and compression consistency.
Calcium phosphate should be evaluated carefully for compatibility, dissolution behavior, and particle-size effects. Lactose may create compatibility or stability concerns depending on the hydrazine chemistry and formulation conditions.
Disintegrant selection
Crospovidone is a logical choice because immediate release is central to the product profile. Croscarmellose sodium and sodium starch glycolate are viable alternatives, but each can alter swelling behavior, dissolution kinetics, and moisture sensitivity.
A dual-disintegrant system could improve robustness, but it would increase formulation complexity without a clear commercial benefit unless development data show superior dissolution after scale-up or storage.
Lubrication strategy
Magnesium stearate should be used at the lowest concentration that provides reliable ejection. Excessive blending can reduce tablet wettability and delay dissolution. Lubricant sensitivity is particularly relevant for a product that depends on rapid release from a compact, high-frequency-dose tablet.
Sodium stearyl fumarate is a possible alternative where improved dissolution or reduced hydrophobicity is needed. It may also support more forgiving processing, although supplier qualification and cost must be assessed.
Glidants and moisture control
Colloidal silicon dioxide can improve flow of the active-excipient blend and reduce segregation risk. Its use should be linked to measured powder-flow and blend-uniformity requirements rather than added as a default.
Packaging is likely to be more important than aggressive excipient loading. High-barrier blister packs or bottles with desiccant protection can reduce moisture-related assay and dissolution drift. The selected container-closure system should be evaluated under long-term and accelerated stability conditions.
What formulation patents protect BiDil and its generics?
The commercial formulation is based on known active ingredients and conventional oral dosage technology. The principal historical intellectual-property value was associated with the combination’s therapeutic use and branded product positioning rather than a highly differentiated excipient platform.
Potentially relevant intellectual-property categories include:
| IP category |
Relevance to this product |
Current commercial significance |
| Fixed-dose combination claims |
Cover co-administration or combined use of the two actives |
Historical importance; likely limited value for current U.S. generic entry |
| Heart-failure method-of-use claims |
Cover treatment in defined patient populations |
May have affected historical labeling and litigation |
| Tablet composition claims |
Could cover specific ratios or excipient systems |
Relevant only if a valid, unexpired claim remains |
| Manufacturing claims |
Could cover granulation, blending, compression, or stability control |
Potentially relevant to a differentiated follow-on product |
| Packaging claims |
Could address moisture protection or dose organization |
Usually narrow and product-specific |
The U.S. Orange Book should be checked for current patent listings associated with NDA 020727 and the marketed BiDil product before any launch or litigation decision.[2] Historical patents associated with BiDil do not automatically create current blocking rights. Patent term, terminal disclaimers, regulatory exclusivity, maintenance fees, claim scope, and Orange Book listing status must be reviewed separately.
When does isosorbide dinitrate and hydralazine hydrochloride lose exclusivity?
The product’s U.S. regulatory exclusivity began with BiDil approval in 2005. The principal new-drug exclusivity period for the fixed-dose combination has expired. Current commercial barriers are therefore more likely to arise from manufacturing, regulatory quality, distribution, and prescriber access than from basic FDA exclusivity.
| Exclusivity element |
Assessment |
| NDA approval |
BiDil approved in 2005 |
| New chemical entity exclusivity |
Not applicable to the fixed-dose combination as marketed |
| Three-year new clinical investigation exclusivity |
Historical period has expired |
| Pediatric exclusivity |
No current blocking period identified |
| Orange Book patents |
Must be confirmed in the current edition |
| Generic pathway |
ANDA pathway is available for products demonstrating pharmaceutical equivalence and bioequivalence |
| Biosimilar pathway |
Not applicable; this is a chemically synthesized small-molecule product |
A generic applicant can challenge listed patents through a Paragraph IV certification if applicable patents remain listed. A Paragraph IV filing requires a notice to the patent holder and may trigger a 45-day period for patent litigation that can impose a statutory stay on approval.[3] The economic value of a Paragraph IV strategy depends on whether a listed patent remains enforceable and whether the applicant has a credible non-infringement or invalidity position.
What is the Orange Book status of BiDil?
BiDil is listed in the FDA Orange Book under NDA 020727. The relevant review should include:
- Current active ingredient and strength listings.
- Current dosage-form and route information.
- Patent numbers and expiration dates listed for the NDA.
- Any use codes associated with method-of-use patents.
- Approved generic products and their therapeutic-equivalence codes.
- Whether listed patents remain relevant to a proposed ANDA filing.
The Orange Book is the controlling starting point for U.S. small-molecule patent and exclusivity analysis, but it is not a complete freedom-to-operate database. Unlisted process, formulation, packaging, trademark, and trade-secret rights can remain commercially relevant.[2]
Which companies are challenging or competing with BiDil?
Competition exists in four groups:
| Competitor group |
Examples |
Competitive effect |
| Generic fixed-dose products |
ANDA-approved isosorbide dinitrate/hydralazine hydrochloride tablets |
Direct price and formulary competition |
| Separate-component generics |
Generic isosorbide dinitrate plus generic hydralazine hydrochloride |
Lower acquisition cost but higher pill burden |
| Standard heart-failure therapies |
Sacubitril/valsartan, beta blockers, mineralocorticoid antagonists, SGLT2 inhibitors |
Compete for treatment budget and regimen priority |
| Alternative vasodilator regimens |
Separate hydralazine and nitrate prescriptions |
Allow flexible dosing but reduce convenience |
The fixed-dose product’s primary advantage over separate components is reduced prescription complexity. Its principal disadvantage is three-times-daily dosing and less flexible titration of the individual drugs.
No biosimilar risk applies because both active ingredients are small-molecule chemical entities. Generic substitution and price erosion are the central competitive risks.
What commercial opportunities exist for excipient innovation?
1. Lower-cost direct-compression manufacturing
A formulation using standard compendial excipients and a short process can compete on cost. Continuous blending, automated weight control, and improved powder-flow control may reduce batch failures and labor requirements.
The highest-value development targets are:
- Better blend uniformity at commercial scale.
- Reduced tablet weight.
- Lower compression-force variability.
- Reduced sticking and picking.
- Stable dissolution after high-humidity storage.
- Fewer processing steps than wet granulation.
2. Moisture-protective packaging
A high-barrier blister or bottle system can support longer shelf life and reduce stability risk. Packaging differentiation may be easier to defend commercially than a routine excipient substitution.
Calendarized blister packaging could organize the three-times-daily regimen. Unit-dose packs may improve institutional dispensing and reduce medication errors.
3. Adherence-oriented dosage forms
Potential concepts include:
- Smaller tablets with higher drug loading.
- Modified tablet geometry for easier swallowing.
- Color-coded strengths.
- Unit-dose adherence packs.
- Orally disintegrating tablets, subject to taste and stability feasibility.
- Combination packaging containing the fixed-dose tablet with other heart-failure medicines.
A sustained-release platform would be more difficult. Isosorbide dinitrate has nitrate-tolerance considerations, and hydralazine has its own pharmacokinetic and tolerability profile. Any modified-release product would require clinical pharmacology, dose-timing, and potentially efficacy bridging work. It should not be treated as a simple 505(j) generic opportunity.
4. Regional and institutional markets
Commercial opportunities are strongest where:
- Generic sourcing is fragmented.
- Heart-failure treatment programs use protocolized therapy.
- Public hospitals favor low-cost fixed-dose combinations.
- Pharmacy systems value unit-dose packaging.
- Local registration allows reliance on established reference-product data.
The product may also be relevant in markets where clinicians prescribe hydralazine and nitrates separately but lack a broadly available fixed-dose product. Registration strategy should account for local treatment guidelines, racial-labeling requirements, pharmacovigilance rules, and local expectations for bioequivalence.
What manufacturing and intellectual-property barriers remain?
The active ingredients are established, but manufacturing quality remains important. Key risks include:
- Blend segregation from differences in particle size and density.
- Assay variability caused by low-dose component distribution.
- Nitrosation or oxidative degradation pathways.
- Moisture-driven changes in dissolution.
- Hydralazine-related impurity control.
- Isosorbide dinitrate assay and degradation monitoring.
- Tablet sticking, capping, and friability.
- Container-closure performance.
- Supplier concentration for critical excipients.
A product with a conventional formula can still fail bioequivalence or stability requirements if particle-size distributions, compression force, lubricant blending, or packaging conditions differ from the reference product.
Trade secrets may have practical value even when patents do not. These can include blending order, lubrication time, environmental humidity limits, compression tooling, impurity-control methods, and packaging specifications.
What litigation and settlement issues affect generic launch?
A prospective applicant should review:
- Orange Book-listed patents for NDA 020727.
- Any FDA patent litigation records tied to BiDil.
- Paragraph IV notices and district-court filings.
- Settlement agreements that impose launch dates or restrictions.
- Antitrust implications of delayed-entry arrangements.
- Trademark and trade-dress risks associated with tablet color or packaging.
Because the product’s main historical patents and exclusivity periods date from the original 2005 approval, the current legal risk is likely to be more limited than for recently approved branded combinations. The precise launch date depends on current Orange Book data and the ANDA’s approval status.
How does BiDil compare with separate-component therapy?
| Factor |
Fixed-dose combination |
Separate generics |
| Tablet burden |
Lower |
Higher |
| Dose flexibility |
Lower |
Higher |
| Prescription complexity |
Lower |
Higher |
| Acquisition cost |
May be higher than two low-cost generics in some markets |
Often competitive |
| Adherence potential |
Better regimen simplicity |
More opportunities for dosing errors |
| Formulation development |
Requires combination bioequivalence |
Established individual products |
| Commercial differentiation |
Packaging and convenience |
Price and supply reliability |
The commercial case for the fixed-dose product depends on whether its convenience offsets any price premium over separate components.
How strong is the patent estate for isosorbide dinitrate and hydralazine hydrochloride?
The core patent estate is mature and likely weak as a barrier to conventional U.S. generic entry compared with newer branded combinations. Strength may remain in narrow areas such as:
- Specific dosage ratios.
- Defined patient populations.
- Modified-release profiles.
- Novel excipient systems.
- Manufacturing controls.
- Packaging configurations.
A new excipient platform can create a separate patent position only if it produces a technically meaningful result, such as improved stability, dissolution, bioavailability, manufacturability, or adherence. Routine substitution of one compendial excipient for another is unlikely to support a strong patent position.
Key Takeaways
- BiDil is an established immediate-release fixed-dose tablet containing 20 mg of isosorbide dinitrate and 37.5 mg of hydralazine hydrochloride.
- The established excipient platform uses conventional direct-compression materials, including microcrystalline cellulose, crospovidone, magnesium stearate, and colloidal silicon dioxide.
- Core U.S. regulatory exclusivity has expired, and the main entry route is an ANDA for a small-molecule generic.
- No biosimilar pathway applies.
- The commercial opportunity is strongest in low-cost manufacturing, moisture-protective packaging, adherence packs, and regional supply.
- Excipient innovation should target stability, dissolution robustness, tablet size, and manufacturing yield.
- A modified-release product would require substantially greater regulatory and clinical development than a conventional generic.
- Current Orange Book listings and Paragraph IV litigation must be checked before making a definitive launch or freedom-to-operate decision.
- The product competes with both fixed-dose generics and separate-component hydralazine and nitrate therapy.
- The patent estate is mature; new patent value would likely require a specific technical improvement rather than routine formulation substitution.
Frequently Asked Questions
Is BiDil a biologic or a small-molecule drug?
BiDil is a small-molecule fixed-dose combination. It contains chemically synthesized isosorbide dinitrate and hydralazine hydrochloride, so generic approval uses the ANDA pathway rather than the biosimilar pathway.
Can isosorbide dinitrate and hydralazine hydrochloride be formulated as a once-daily tablet?
A once-daily product would require a modified-release formulation and new pharmacokinetic and clinical development. It cannot be assumed to qualify as a routine generic equivalent to the immediate-release reference product.
Which excipient is most important for rapid release?
Crospovidone is a key immediate-release excipient in the established formulation. Its performance depends on grade, particle size, concentration, compression force, and lubricant exposure.
Does a fixed-dose tablet always reduce treatment cost?
No. It can reduce pill burden and dispensing complexity, but two separate generic products may have a lower acquisition cost depending on market pricing, reimbursement, and supply contracts.
Can a new packaging system be patented?
Potentially, but the claims must cover a novel and non-obvious packaging configuration or functional result. Routine use of a standard bottle, blister, or desiccant is unlikely to create a strong standalone patent position.
References
-
U.S. Food and Drug Administration. (2023). BiDil (isosorbide dinitrate and hydralazine hydrochloride) tablets: Prescribing information. Arbor Pharmaceuticals, LLC.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2019). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.
-
U.S. Food and Drug Administration. (2025). Inactive ingredient database. FDA.
-
U.S. Pharmacopeial Convention. (2025). United States Pharmacopeia and National Formulary. USP.
